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To compare the interobserver agreement and degree of confidence in anatomical localisation of lesions using 2-[fluorine-18]fluoro-2-
deoxy-D-glucose (
18F-FDG) positron emission tomography (PET)/computed tomography (CT) and
18F-FDG PET alone in patients
with head and neck tumours. A prospective study of 24 patients (16 male, eight female, median age 59 years) with head and neck
tumours was undertaken.
18F-FDG PET/CT was performed for staging purposes. 2D images were acquired over the head and neck
area using a GE Discovery LSt PET/CT scanner.
18F-FDG PET images were interpreted by three independent observers. The
observers were asked to localise abnormal
18F-FDG activity to an anatomical territory and score the degree of confidence in
localisation on a scale from 1 to 3 (1¼exact region unknown; 2¼probable; 3¼definite). For all
18F-FDG-avid lesions, standardised
uptake values (SUVs) were also calculated. After 3 weeks, the same exercise was carried out using
18F-FDG PET/CT images, where
CT and fused volume data were made available to observers. The degree of interobserver agreement was measured in both
instances. A total of six primary lesions with abnormal
18F-FDG uptake (SUV range 7.2–22) were identified on
18F-FDG PET alone
and on
18F-FDG PET/CT. In all, 15 nonprimary tumour sites were identified with
18F-FDG PET only (SUV range 4.5–11.7), while 17
were identified on
18F-FDG PET/CT. Using
18F-FDG PET only, correct localisation was documented in three of six primary lesions,
while
18F-FDG PET/CT correctly identified all primary sites. In nonprimary tumour sites,
18F-FDG PET/CT improved the degree of
confidence in anatomical localisation by 51%. Interobserver agreement in assigning primary and nonprimary lesions to anatomical
territories was moderate using
18F-FDG PET alone (kappa coefficients of 0.45 and 0.54, respectively), but almost perfect with
18F-
FDG PET/CT (kappa coefficients of 0.90 and 0.93, respectively). We conclude that
18F-FDG PET/CT significantly increases
interobserver agreement and confidence in disease localisation of
18F-FDG-avid lesions in patients with head and neck cancers.
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Squamous cell carcinoma is the most common tumour type in
head and neck cancers (Ak et al, 2000). At presentation, 40% of
patients have localised disease, while 60% have advanced
malignancies (Ak et al, 2000). Cervical lymph nodes are the most
common site for tumour spread (Mendenhall et al, 1998; Ak et al,
2000), and this is a relatively common clinical presentation
(Mendenhall et al, 1998; Ak et al, 2000). The presence or absence of
cervical lymphadenopathy is of prognostic significance (Myers
et al, 1998).
The role of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (
18F-FDG)
positron emission tomography (PET) imaging has previously been
evaluated in head and neck tumours, the reported sensitivity and
specificity varying between 90 and 96% in primary and treated
disease (Myers et al, 1998). Determining the precise location of
18F-FDG-avid lesions by PET alone can be challenging in these
patients, as the test suffers from poor anatomical localisation that
might compromise sensitivity (Ak et al, 2000). The recent
introduction of combined
18F-FDG PET and computed tomogra-
phy (CT) imaging has revolutionised imaging by allowing accurate
anatomical localisation of functional abnormalities. However, no
large trial has as yet confirmed this advantage in head and neck
tumours.
The aim of this pilot study was to assess the degree of
interobserver agreement and confidence in anatomical localisation
of primary head and neck tumours and their metastases with
18F-
FDG PET alone and with
18F-FDG PET/CT.
MATERIALS AND METHODS
Patient group
Between June 2000 and August 2003, 24 patients with histologically
proven head and neck tumours who underwent whole-body
18F-
FDG PET/CT for staging were included in a prospective study. This
study, examining the imaging strength of
18F-FDG PET/CT, is part
of an ongoing prospective trial looking at the role of
18F-FDG PET
scintigraphy in head and neck cancer. The study was approved by
the local ethics committee.
Inclusion criteria
The inclusion criteria were: histologically confirmed diagnosis of
head and neck cancer and absence of prior chemotherapy,
radiotherapy or surgery to the head and neck region.
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All patients went through a standard protocol with a minimum of
6h fasting prior to the study in order to minimise glucose
utilisation by normal tissue. Patients were given a muscle relaxant
just before the injection (5mg diazepam orally) to reduce muscle
uptake. Blood glucose level was checked prior to
18F-FDG
injection, and if it was less than 10mmoll
 1, the patient was
intravenously injected with
18F-FDG (mean injected activi-
ty¼380MBq, range 370–400MBq) calibrated just before the
injection. Patients rested for 45min before imaging and were
advised to remain silent to reduce skeletal muscle uptake.
DATA acquisition and reconstruction
PET/CT was performed using the GE Advance PET scanner and the
GE Light-speed multislice spiral CT. The Light-speed CT acquires
four 5-mm slices at 140kV with 80mA and a large pitch of 6
(30mm of table travel per gantry rotation).
CT protocol
Four-detector multislice CT images were acquired using speed of
rotation and couch movement of 0.8s and 30mm per rotation,
respectively. The images were reconstructed in 4.25mm slice width
during normal respiration. CT images were rebinned from a
512 512 matrix to a 128 128 matrix and matched to the pixel
size of the PET data in order to match the in-slice resolution of the
PET emission images. The CT images were subsequently converted
to maps of PET attenuation coefficients using a bilinear
transformation based on the use of different scaling factors for
materials with Hounsfield units (HU) p0 and 40.
PET protocol
Without changing the patient position, a whole-body PET
emission scan was performed over the same area as was covered
by CT (five to six bed positions). All acquisitions were carried
out in 2D mode, the protocol comprising an emission scan with
5min per bed position. PET images were reconstructed using
CT attenuation maps. Transaxial emission images of
4.3 4.3 4.25mm
3 (in plane matrix size 128 128, 35 slices per
bed position) were reconstructed using ordered subsets expecta-
tion maximisation (OSEM) with two iterations and 28 subsets. The
axial field of view was 148.75mm, with acquisition of 35 slices per
bed position.
Analysis
Two nuclear medicine physicians and one radiologist (blinded to
the results of clinical and other radiological findings) were
informed that they were evaluating studies in patients with head
and neck cancers. Each reporter interpreted the studies indepen-
dently. The
18F-FDG PET scans were reviewed first and the
18F-
FDG PET/CT images were interpreted 3 weeks later.
The readers were asked to identify abnormal sites of increased
uptake and assign a score as follows:
a. Activity at or above brain cerebral cortex: score of 3.
b. Activity between that of brain and liver: score of 2.
c. Activity any less than b: score of 1.
Lesions were considered positive if they had an
18F-FDG uptake
score of at least 2. These areas were also quantitatively assessed
with measurements (standard uptake values (SUVs)) using region
of interest (ROI) analysis. Irregular ROIs were drawn over the most
avid part of the identified lesion, the margin being identified
visually on a grey scale of 0–20000Bqml
 1. Mean and maximal
values of the
18F-FDG uptake were determined.
Inter-reader variability for all of the reporting tasks outlined was
assessed using kappa statistics: kappa values of 40.8, 0.61–0.8 and
0.41–0.6 represented perfect, substantial and moderate agreement,
respectively (Cohen, 1960; Landis and Koch, 1977; Fleiss, 1981).
The confidence in anatomically localising the primary lesion was
also assessed. Areas of abnormal increase in
18F-FDG activity were
assigned to an anatomical territory, and the degree of confidence
in anatomical localisation was scored on a scale of 1–3 as follows:
a. Exact anatomical region doubtful: score of 1.
b. Probable anatomical localisation: score of 2.
c. Definite anatomical localisation: score of 3.
RESULTS
The study group included 16 males and eight females with a
median age of 59 years (range 36–86 years). Of the 24 patients, 12
had squamous cell carcinoma of the aerodigestive tract (located in
the hypopharynx in eight cases and in the oropharynx in four), as
confirmed by the postoperative surgical specimen. In the
remaining patients, no primary lesion was identified but nodal
disease was confirmed histologically (as metastatic squamous cell
carcinoma deposits).
Abnormal activity on PET
Of the 24 patients, 18 had positive and six negative
18F-FDG PET
scans. In the aforementioned 18 patients, 21
18F-FDG-avid lesions
were identified, of which six were primary tumours (SUV range
7.2–22) and 15 were nonprimary lesions (SUV range 4.5–11.7).
Anatomical localisation: PET only
18F-FDG PET identified the anatomical site correctly in only 12 of
the 21
18F-FDG-avid lesions (57%): three (25%) were primary
tumour sites and nine (75%) were sites of nonprimary lesions. No
specific anatomical sites could be identified in nine of the 21
lesions (43%), comprising three primary and six nonprimary
lesions.
Anatomical localisation: PET/CT
18F-FDG PET/CT images identified 21
18F-FDG-avid lesions in 18
patients. Of these 21 lesions, six were primary lesions and 15 were
nonprimary lesions. Of the 15 nonprimary lesions, two were
located in the neck muscles, two in fat planes (a normal variant),
nine at nodal sites, one in lung and one in a rib (Table 1).
Enhanced CT identified two additional lesions, which showed no
18F-FDG uptake and which were subsequently confirmed to be
benign enlarged cervical nodes on histology.
Lesion-based analysis
The total number of lesions identified by each observer using
18F-
FDG PET alone and
18F-FDG PET/CT was similar. The inter-
observer variability in assigning FDG-avid lesions to an anatomical
territory when using
18F-FDG PET alone and
18F-FDG PET/CT is
shown in Table 2. Using
18F-FDG PET/CT, the confidence in
anatomical localisation improved by 57% for observer 1, 43% for
observer 2 and 52% for observer 3 (Table 3).
Using
18F-FDG PET alone, correct anatomical localisation was
documented in 50% of primary lesions and 60% of nonprimary
lesions. Using
18F-FDG PET/CT, confidence in assigning lesions to
an anatomical territory improved by 50% in primary sites and 51%
in nonprimary sites.
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The calculated interobserver agreement for the three observers in
identifying
18F-FDG-avid primary and nonprimary sites was
almost perfect (100%) with both
18F-FDG PET alone and
18F-
FDG PET/CT. However, when using
18F-FDG PET alone, there was
only moderate agreement between the three observers in assigning
primary and nonprimary lesions to anatomical territories, with
kappa coefficients of 0.45 and 0.54, respectively (Table 4). On the
other hand, there was strong agreement between all three
observers in assigning both primary and nonprimary lesions to
anatomical territories when using
18F-FDG PET/CT, with kappa
coefficients of 0.90 and 0.93, respectively (Table 4).
DISCUSSION
This study shows the advantage of
18F-FDG PET/CT over
18F-FDG
PET alone in disease localisation in patients with head and neck
cancers. Our data demonstrate strong interobserver agreement in
lesion localisation between the three readers on
18F-FDG PET/CT
but not on
18F-FDG PET alone. The study also shows that
18F-FDG
PET/CT improves the confidence in assigning lesions to an
anatomical territory by 50% in primary and 51% in nonprimary
sites, compared with
18F-FDG PET alone (Figure 1).
These results are of clinical significance in the head and neck
territory, where the anatomy is complex. Use of
18F-FDG PET
alone suffers from lack of anatomical outline identification, which
makes precise localisation difficult. In turn, this renders image
analysis difficult, and may give rise to false-positive findings. We
observed four false-positive sites in our study as follows: in four
patients, false-positive lesions were identified in the neck on
18F-
FDG PET alone. These were asymmetrical in distribution and were
considered positive nodal metastases; however,
18F-FDG PET/CT
clearly localised these to brown fat planes and muscle uptake
(Table 1). It is well known that nonspecific uptake in brown fat
planes and muscle attachment sites (Figure 2E) is a common cause
of false-positive results (Engel et al, 1996; Kostakoglu et al, 1996;
McGuirt et al, 1998). This false-positive feature has a critical
Table 1 Comparison between
18F-FDG PET alone and
18F-FDG PET/CT in identifying
18F-FDG-avid primary and nonprimary lesions
Nonprimary lesions
Primary
lesions
Lymph
nodes
a
Fat
uptake Muscle Lung Rib
18F-FDG PET 6 13 Hot spot reported
(unable to define
anatomical territory)
Hot spot reported
(unable to define
anatomical territory)
1 Hot spot reported
(unable to define
anatomical territory)
1 Hot spot reported
(unable to define
anatomical territory)
18F-FDG PET/CT 6 9 2 2 1 Confirmed on high-resolution CT 1 Confirmed on bone scan
18F-FDG PET¼2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT¼computed tomography.
aIncludes four lesion identified as activity in the lymph nodes on
18F-FDG PET and were
subsequently confirmed to be fat and muscle uptake on
18F-FDG PET/CT.
Table 2 Interobserver variability in assigning
18F-FDG-avid lesions to an
anatomical territory using
18F-FDG PET alone and
18F-FDG PET/CT
No. of FDG-avid lesions
with each score/total
no. of FDG-avid lesions
Confidence
score for
anatomical
localisation
of lesions
18F-FDG PET alone
18F-FDG PET/CT
Observer 1 1 6/21 2/21
2 5/21 1/21
3 10/21 18/21
Observer 2 1 2/21 0/21
2 4/21 4/21
3 15/21 17/21
Observer 3 1 1/21 0/21
2 3/21 2/21
3 17/21 19/21
18F-FDG PET¼2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT¼computed tomo-
graphy.
Table 3 Improvement in confidence of each observer in assigning
18F-
FDG-avid lesions to an anatomical territory when using
18F-FDG PET/CT,
as compared with
18F-FDG PET alone
18F-FDG
PET alone
18F-FDG
PET/CT
Lesion
detect-
ability
Anatomical
localisation
Lesion
detect-
ability
a
Anatomical
localisation
a
(%) Improve-
ment
Observer 1 21 12 23 23 57
Observer 2 21 9 23 23 43
Observer 3 21 11 23 23 52
51% 100% 51
18F-FDG PET¼2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT¼computed tomogra-
phy.
aIncludes two lesions identified on enhanced CT, which did not show
18F-FDG
uptake and were subsequently confirmed to be benign enlarged cervical nodes on
histology.
Table 4 Kappa coefficient with 95% confidence intervals between three
observers using
18F-FDG PET alone and
18F-FDG PET/CT
18F-FDG PET alone
18F-FDG PET/CT
Kappa
coefficient
95% Confidence
interval
Kappa
coefficient
95%
Confidence
interval
Site of primary 1 0.88–1.12 1 0.88–1.11
Localisation of tumour 0.45 0.27–0.62 0.90 0.82–1.02
No. of nodes 1 0.9–1.09 1 0.9–1.09
Localisation of nodes 0.54 0.31–0.72 0.93 0.89–1.06
18F-FDG PET¼2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT¼computed tomo-
graphy.
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et al, 1996; Myers et al, 1998; Hannah et al, 2002). The possibility
of false-positive sites on
18F-FDG PET alone also holds true in the
postsurgical and postradiotherapy neck, where distortion of
normal anatomy can further add to the complexity. In this
context, the ability to fuse
18F-FDG uptake to an anatomical
structure defined on CT carries a significant advantage in reducing
false-positive results. In our study,
18F-FDG PET/CT downstaged
the disease in the aforementioned cases, and the management was
changed from wide neck dissection to local radiotherapy and local
surgery.
In our hands,
18F-FDG PET/CT demonstrated a sensitivity of
91% and a specificity of 93% in identifying disease. Similar results
for PET/CT have been reported previously (Meltzer et al, 2001).
For
18F-FDG PET, Laubenbacher et al (1995) reported a sensitivity
of 90% and a specificity of 96%, Bailet et al (1992) a sensitivity of
71% and a specificity of 98% and Braams et al (1995) a sensitivity
of 91% and a specificity of 88%.
In this study, we correctly identified nine
18F-FDG-avid
metastatic cervical lymph nodes (seven (78%) ipsilateral and two
(22%) contralateral). In addition, two non-nodal metastases were
identified (one in lung and one in rib). These latter two lesions
were reported with both
18F-FDG PET and
18F-FDG PET/CT, but
accurate anatomical localisation was only possible with
18F-FDG
PET/CT (Table 1). Subsequently, both patients received palliative
treatment for symptom relief. This highlights the advantage of
whole-body
18F-FDG PET in identifying distant metastases (M
staging). The ability to detect unexpected contralateral neck
disease, second primary tumours and distant metastases by
whole-body
18F-FDG PET/CT imaging has clear implications and
may dramatically alter treatment planning, with the emphasis
shifting to a less aggressive approach. Thus, it is important that
whole-body
18F-FDG PET/CT scanning is performed in these
patients to detect distant metastases, and that imaging should not
be restricted to the head and neck area because of time constraints.
18F-FDG PET/CT also identified the primary lesion in two
patients who presented with metastatic neck disease and in whom
the primary could not be identified despite conventional
investigations. The ability to detect the primary with
18F-FDG
PET/CT has significant management implications (Kluetz et al,
2000). In such cases, definitive treatment can be instituted at the
primary site, rather than irradiating potential sites empirically or,
as is the practice at some centres, instituting an expectant policy
and managing the primary site if and when it becomes clinically
evident. Furthermore, by pinpointing the areas of involvement, the
surgeon can better define margins and spare structures that are not
affected by malignancy.
Finally, although not part of this particular study, another aspect
of patient management where combined PET/CT can be beneficial
is in the investigation of recurrent disease and evaluation of
response to therapy. This can be exceptionally difficult with
conventional imaging alone, and is currently managed by repeated
EUA/endoscopy and ‘best guess biopsy’. Such an approach is often
Figure 1 A 50-year-old male with squamous cell carcinoma of the
tongue. (A) Multiple intensity projection
18F-FDG PET image. (B) Sagittal
and (C) transaxial images show abnormal uptake in the right cervical region
and right premolar area; dental pathology is present (yellow arrow). (D)
CT transaxial section reveals level II enlarged lymph nodes. (E) Fused
18F-
FDG PET/CT transaxial section at the same level reveals that one lymph
node is FDG positive (red arrow), while the other nodes shows no avidity
for FDG (green arrows). The fused images clearly localised the exact site of
involvement.
Figure 2 A 42-year-old male with squamous cell carcinoma of tongue.
(A)
18F-FDG PET/CT multiple intensity projection image shows the
primary site (red arrow) with bilateral cervical nodes (blue arrows). (B)
Sagittal and (C) transaxial images show abnormal uptake in the known
primary (posterior part of the tongue) and both cervical regions. (D)C T
transaxial section reveals a lesion in the base of the tongue along with left
cervical node enlargement. (E) Fused
18F-FDG PET/CT transaxial section at
the same level reveals the exact anatomical site of
18F-FDG uptake in the
right side of the tongue base extending across the midline and level II left
cervical lymph node. The
18F-FDG activity in the right cervical region
correlates to the right sternocleidomastoid muscle (green arrow) (a normal
variant).
18F-FDG PET/CT in head and neck tumours
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implications.
Our data further highlight the advantage of
18F-FDG PET/CT
and show identical interobserver agreement in lesion detection and
localisation between the three readers on
18F-FDG PET/CT but not
on
18F-FDG PET alone. This was despite the variation in speciality
(nuclear medicine and radiology) of the readers. It might be
argued that this improvement was subjective and was biased by the
observer’s knowledge of the type of scan used. However, the
significant improvement in interobserver agreement between the
three observers refutes the above line of reasoning and serves to
validate the argument that the improved confidence among the
three observers was a reflection of improved anatomical localisa-
tion by
18F-FDG PET/CT in real terms.
Some limitations of this study need to be mentioned. The small
size of the patient cohort limited accurate assessment of sensitivity
and specificity of
18F-FDG PET/CT. Furthermore, the cohort under
study were treatment naive; after surgery and radiotherapy,
different rates of detection of residual or recurrent disease would
be expected with
18F-FDG PET/CT and
18F-FDG PET alone.
CONCLUSION
 
18F-FDG PET alone suffers from poor anatomical localisation of
head and neck cancers and their metastases.
 
18F-FDG uptake at sites of brown fat/muscle attachment can
mimic cervical nodal metastases on
18F-FDG PET alone but not
on
18F-FDG PET/CT.
 
18F-FDG PET/CT demonstrates strong interobserver agreement
and improves confidence in anatomical localisation of
18F-FDG-
avid disease by approximately 50%.
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